Medication · US & Canada
Zepbound, explained
By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due May 1, 2027
Clinical review: not yet reviewed by a clinician. How review works · Editorial policy
Zepbound is Eli Lilly's tirzepatide brand for weight management and, since late 2024 in the US, for obstructive sleep apnea in adults with obesity[1][2].
Status in the US and Canada
| Item | United States | Canada |
|---|---|---|
| Weight management | Adults with obesity, or overweight with a weight-related condition | Adults with BMI 30+, or 27 to under 30 with a related condition |
| Children | Not authorized | Not authorized |
| Sleep apnea | Moderate-to-severe, adults with obesity | Adults with obesity (BMI 30+) |
Forms
A once-weekly injection in single-dose pens and vials, multi-dose vials and the KwikPen, in 2.5 to 15 mg strengths[1]. The label says not to use it with other tirzepatide products or any GLP-1 receptor agonist[1].
The trials behind it
The 2023 approval was based on SURMOUNT-1 and SURMOUNT-2; the sleep-apnea approval on two 52-week trials in 469 adults without type 2 diabetes[3][2].
Study: SURMOUNT-1[6]
How much weight loss does weekly tirzepatide produce compared with placebo in adults with obesity and no diabetes?
- Who was in it
- 2,539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, without diabetes
- What they got
- Tirzepatide 5, 10 or 15 mg injection once a week, with lifestyle counselling
- Compared with
- Placebo, with lifestyle counselling
- How long
- 72 weeks
- What happened
- Average weight change: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% on placebo.
- Limits
- People with diabetes were excluded
- 72 weeks: no heart outcomes
- Did not test what happens after stopping
- Funded by
- Eli Lilly
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Study: SURMOUNT-OSA[7]
Does tirzepatide reduce the severity of obstructive sleep apnea in adults with obesity?
- Who was in it
- 469 adults with moderate-to-severe sleep apnea and obesity, without type 2 diabetes, in two trials (with and without CPAP)
- What they got
- Tirzepatide at the highest tolerated dose (10 or 15 mg) once a week
- Compared with
- Placebo
- How long
- 52 weeks
- What happened
- Breathing interruptions per hour (AHI) fell by 25.3 vs 5.3 (trial 1) and 29.3 vs 5.5 (trial 2) on tirzepatide vs placebo.
- Limits
- People with diabetes were excluded
- 52 weeks
- The effect may be largely through weight loss
- Funded by
- Eli Lilly
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Related
Tirzepatide · Mounjaro · Mounjaro & Zepbound cost
General information, not medical advice. Which product and dose is right for you is a decision for you and your prescriber. Light Years earns nothing from any product named here.
Log each dose and see when the next one is due, on your device. Open my tracker or browse the other guides.
Sources
- ZEPBOUND (tirzepatide) injection — prescribing information. U.S. Food and Drug Administration (FDALabel), August 2026. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/487cd7e7-434c-4925-99fa-aa80b1cc776b/spl-doc. Accessed November 2, 2026. Back to the text
- FDA approves first medication for obstructive sleep apnea. U.S. Food and Drug Administration, December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea. Accessed November 2, 2026. Back to the text
- FDA approves new medication for chronic weight management. U.S. Food and Drug Administration, November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management. Accessed November 2, 2026. Back to the text
- Zepbound (tirzepatide injection) KwikPen product monograph. Health Canada Drug Product Database / Eli Lilly Canada, April 2, 2026. https://pdf.hres.ca/dpd_pm/00084150.PDF. Accessed November 2, 2026. Back to the text
- Health Canada approves Zepbound as the first-ever obstructive sleep apnea medication (Eli Lilly Canada release). Eli Lilly Canada (via BioSpace), June 16, 2026. https://www.biospace.com/press-releases/health-canada-approves-zepbound-as-the-first-ever-obstructive-sleep-apnea-medication-in-canada-for-adults-living-with-obesity. Accessed November 2, 2026. Back to the text
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, July 21, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/ · DOI 10.1056/NEJMoa2206038 · PMID 35658024. Accessed November 2, 2026. Back to the text
- Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). New England Journal of Medicine, October 3, 2024. https://pubmed.ncbi.nlm.nih.gov/38912654/ · DOI 10.1056/NEJMoa2404881 · PMID 38912654. Accessed November 2, 2026. Back to the text
Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.
Changes to this page
- — First published.
Substantive corrections are also logged at corrections.